Recent Updates
Recently added Catalysts
PRLD Neutral Sentiment

Clinical Biomarkers Based on PK/PD Modeling to Guide the Development for a First-in-Class, Highly Selective SMARCA2 (BRM) Degrader, PRT3789

Friday, October 20, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the development of PRT3789, a first-in-class SMARCA2 (BRM) degrader. It highlights the importance of clinical biomarkers based on pharmacokinetic/pharmacodynamic (PK/PD) modeling in guiding its development. The focus is on the scientific and strategic aspects of the drug's progression within Prelude Therapeutics' pipeline.
Price reaction · baseline $2.32 (2023-10-19 close) · hit pre-market · 1 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
+3%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

• About Overview Leadership Board of Directors
• Science Overview Pipeline JAK2V617F KAT6A Precision DACs Discovery Engine Publications
• Investors Overview News & Events News Releases Events & Presentations Financials SEC Filings Quarterly Results Stock Information Stock Quote & Chart Analysts Governance Governance Documents Leadership Committee Composition Investor Resources Investor Faqs Contact IR Email Alerts
• News
• Life at Prelude Overview Open Positions
• Contact
• Overview
• Leadership
• Board of Directors
• Overview
• Pipeline
• JAK2V617F
• KAT6A
• Precision DACs
• Discovery Engine
• Publications
• Overview
• News & Events News Releases Events & Presentations
• Financials SEC Filings Quarterly Results
• Stock Information Stock Quote & Chart Analysts
• Governance Governance Documents Leadership Committee Composition
• Investor Resources Investor Faqs Contact IR Email Alerts
• News Releases
• Events & Presentations
• SEC Filings
• Quarterly Results
• Stock Quote & Chart
• Analysts
• Governance Documents
• Leadership
• Committee Composition
• Investor Faqs
• Contact IR
• Email Alerts
• Overview
• Open Positions
Min Wang, Andrew Moore, Alex Grego, Miles Cowart, Joseph Rager, Gina Paris, Koichi Ito, Naveen Babbar, Sandy Geeganage, Peggy Scherle, Neha Bhagwat
ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT3789 SMARCA2 biomarkers PK/PD modeling Prelude Therapeutics
Last updated: Oct 20, 2023

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →